GSK, other drugmakers bet on post-Brexit UK scienceLONDON (Reuters) - Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government s industrial strategy plans after Brexit. The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union. Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.  But the highly regulated sector faces potential obstacles to trade as a result of Brexit unless London and Brussels manage to align regulatory regimes for medicines. In a bid to soften the blow, the government has backed a report by immunologist and geneticist John Bell designed to boost the pharmaceutical sector via fresh public-private collaborations. That has paved the way for the Life Sciences Sector Deal, which will see GSK invest 40 million pounds ($54 million) of new money in genomic research, including a plan to sequence DNA from all 500,000 volunteer participants enrolled in UK Biobank, the world s most detailed biomedical database. GSK s head of research Patrick Vallance said the deal showed Britain remained an attractive place for drug discovery, but he cautioned:  The UK needs to recognize going forward that science is an international endeavor, not a parochial endeavor.  Other investments by pharma companies include plans by Johnson & Johnson and the Medicines Co to work on new clinical trials and genetic research by AstraZeneca. U.S. drugmaker Merck & Co had already announced plans to expand UK research operations under the deal last week. In all, the government said the deal brought together existing and future commitments by 25 global organizations. Other companies in discussions with the government about investments include Philips, Roche Diagnostics, Siemens, GE Healthcare and Toshiba Medical Systems. As a key part of the deal, the government said it was committed to increasing investment in R&D to 2.4 percent of GDP by 2027 and 3 percent over the longer term. worldnews
ask drugmakers bet uk sciencelondon reuters britain vote confidence economically important life sciences sector wednesday several major drug companies committed invest country government industrial strategy plans brexit the move welcome news prime minister theresa may struggled win large sections industry britain prepares leave european union thanks strength uk universities presence two major pharmaceuticals companies glaxosmithkline astrazeneca drugs industry bright spot british economy many years but highly regulated sector faces potential obstacles trade result brexit unless london brussels manage align regulatory regimes medicines in bid soften blow government backed report immunologist geneticist john bell designed boost pharmaceutical sector via fresh collaborations that paved way life sciences sector deal see ask invest million pounds million new money genomic research including plan sequence dna volunteer participants enrolled uk biobank world detailed biomedical database ask head research patrick balance said deal showed britain remained attractive place drug discovery cautioned the uk needs recognize going forward science international endeavor parochial endeavor other investments pharma companies include plans johnson johnson medicines co work new clinical trials genetic research astrazeneca drugmaker mercy co already announced plans expand uk research operations deal last week in government said deal brought together existing future commitments global organizations other companies discussions government investments include philip roche diagnostics siemens ge healthcare toshiba medical systems as key part deal government said committed increasing investment r d percent gdp percent longer term worldnews
Your task is to classify the provided input as real or fake news. Label 0 is meant for fake news, Label 1 is for real news. TEXT: GSK, other drugmakers bet on post-Brexit UK scienceLONDON (Reuters) - Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government s industrial strategy plans after Brexit. The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union. Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.  But the highly regulated sector faces potential obstacles to trade as a result of Brexit unless London and Brussels manage to align regulatory regimes for medicines. In a bid to soften the blow, the government has backed a report by immunologist and geneticist John Bell designed to boost the pharmaceutical sector via fresh public-private collaborations. That has paved the way for the Life Sciences Sector Deal, which will see GSK invest 40 million pounds ($54 million) of new money in genomic research, including a plan to sequence DNA from all 500,000 volunteer participants enrolled in UK Biobank, the world s most detailed biomedical database. GSK s head of research Patrick Vallance said the deal showed Britain remained an attractive place for drug discovery, but he cautioned:  The UK needs to recognize going forward that science is an international endeavor, not a parochial endeavor.  Other investments by pharma companies include plans by Johnson & Johnson and the Medicines Co to work on new clinical trials and genetic research by AstraZeneca. U.S. drugmaker Merck & Co had already announced plans to expand UK research operations under the deal last week. In all, the government said the deal brought together existing and future commitments by 25 global organizations. Other companies in discussions with the government about investments include Philips, Roche Diagnostics, Siemens, GE Healthcare and Toshiba Medical Systems. As a key part of the deal, the government said it was committed to increasing investment in R&D to 2.4 percent of GDP by 2027 and 3 percent over the longer term. worldnews
Your task is to classify the provided input as real or fake news. Label 0 is meant for fake news, Label 1 is for real news. TEXT: ask drugmakers bet uk sciencelondon reuters britain vote confidence economically important life sciences sector wednesday several major drug companies committed invest country government industrial strategy plans brexit the move welcome news prime minister theresa may struggled win large sections industry britain prepares leave european union thanks strength uk universities presence two major pharmaceuticals companies glaxosmithkline astrazeneca drugs industry bright spot british economy many years but highly regulated sector faces potential obstacles trade result brexit unless london brussels manage align regulatory regimes medicines in bid soften blow government backed report immunologist geneticist john bell designed boost pharmaceutical sector via fresh collaborations that paved way life sciences sector deal see ask invest million pounds million new money genomic research including plan sequence dna volunteer participants enrolled uk biobank world detailed biomedical database ask head research patrick balance said deal showed britain remained attractive place drug discovery cautioned the uk needs recognize going forward science international endeavor parochial endeavor other investments pharma companies include plans johnson johnson medicines co work new clinical trials genetic research astrazeneca drugmaker mercy co already announced plans expand uk research operations deal last week in government said deal brought together existing future commitments global organizations other companies discussions government investments include philip roche diagnostics siemens ge healthcare toshiba medical systems as key part deal government said committed increasing investment r d percent gdp percent longer term worldnews